Study of the mechanism of action of Blarcamesine (ANAVEX®2‐73): Whole blood transcriptomics analysis identifies treatment impact on compensatory pathways by restoring key neurodegenerative pathways functionality, including Alzheimer’s disease pathway
Abstract:Background
Blarcamesine (ANAVEX®2‐73), a novel oral selective sigma‐1 receptor (SIGMAR1) agonist was investigated in a clinical Phase 2a study in Alzheimer’s disease in which blarcamesine resulted in a lower rate of cognitive (MMSE) and functional (ADCS‐ADL) decline. Following the positive results of this study, a translational approach led to investigating blarcamesine in an international, double‐blind, multicenter, placebo‐controlled Phase 2 clinical study of 14‐week duration in 132 patients with Parkinson’s… Show more
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.